Date: 2016-04-19
Type of information: Establishment of a new subsidiary in the US
Compound: Anagenesis Biotherapies Inc
Company: Anagenesis Biotechnologies (France)
Therapeutic area: Rare diseases - Genetic diseases - Neuromuscular diseases
Type agreement: establishment of a new subsidiary in the US
Action mechanism:
Disease:
Details: * On April 19, 2016, Anagenesis Biotechnologies, a company developing stem cell-derived treatments for muscle diseases announced the creation of its US subsidiary, Anagenesis Biotherapies Inc. in Boston, Massachusetts. The US subsidiary will carry out the company’s cell therapy programs with an initial focus on Duchenne muscular dystrophy, paving the way for future partnerships. Anagenesis owns a unique stem cell differentiation technology that allows the massive and standardized production of different lineages including mature skeletal muscle cells. Using this technology, the company is currently developing two R&D programs for muscle disorders. The first one is a cell therapy for Duchenne muscular dystrophy. The other program is focused on the development of high throughput/high content screening using customized in vitro assays to identify leadcompounds acting on muscle progenitors for sarcopenia and cachexia, two muscle disorders associated with aging and cancer, respectively. Following the publication of Anagenesis’ technology in Nature Biotechnology last August, the company has been actively involved in discussions with US-based biopharma and patients associations. The establishment of Anagenesis’ operations in Massachusetts will allow the company to come Anagenesis Biotechnologies develops new treatments against muscle diseases such as Duchenne muscular dystrophy, sarcopenia and cachexia. The company was cofounded in 2011 by Pr. Olivier Pourquié, a worldwide key opinion leader in the field of musculoskeletal development and stem cells, and Christopher Henderson. one of Trophos' co-founders. Anagenesis Biotechnologies is backed by a team led by its President & CEO, Dr Jean-Yves Bonnefoy.
closer to its future partners and constitutes a strategic step to advance the company’s Duchenne muscular dystrophy cell therapy program.
Financial terms:
Latest news:
